Fortress Biotech, Inc. 8-K

What Happened

• Fortress Biotech (FBIO) filed an 8-K reporting that its majority-owned subsidiary Cyprium Therapeutics, Inc. entered a definitive asset purchase agreement on February 22, 2026 to sell a Rare Pediatric Disease Priority Review Voucher (PRV) for $205 million in cash, subject to customary closing conditions (including Hart-Scott-Rodino review). The PRV was issued with FDA approval of ZYCUBO® for Menkes disease.
• On the same date, Fortress entered a Second Amendment to its Credit Agreement with Oaktree (amending the July 25, 2024 loan and a December 12, 2025 first amendment). Fortress originally borrowed $35.0 million and is eligible for up to an additional $15.0 million; about $29.5 million was outstanding as of the report date.

Key Details

• PRV sale price: $205 million cash payable at closing (PRV APA dated Feb 22, 2026). Sale remains subject to customary closing conditions.
• Fortress ownership: Company owns 80.4% of Cyprium’s outstanding common stock (as-converted basis).
• Expected proceeds to Fortress: Fortress expects to receive at least $100.0 million in aggregate from Cyprium via future dividends and intercompany amounts, but the final amount depends on factors such as a required 20% payment to an NIH institute, taxes, preferred stock redemption, board-approved dividends, and other obligations.
• Loan amendment effects: If (a) outstanding loan principal is ≤ $15.0M and Fortress receives the Cyprium distribution from the PRV sale, then Minimum Liquidity is set at $2.0M and several covenants (Minimum Net Sales, Capital Raise, Minimum JMC Stake) are suspended. All four covenants will also be removed if loan principal ≤ $10.0M. The amendment also requires: (i) repayment by Cyprium of advances made by Fortress under a related promissory note and (ii) a mandatory $10.0M aggregate principal prepayment of the loan (plus accrued interest and Yield Protection Premium) in connection with the Cyprium monetization event, subject to fees and conditions.

Why It Matters

• A $205M PRV sale could materially increase cash available to Fortress through its 80.4% stake in Cyprium; management expects at least $100M in aggregate receipts but clarifies the amount is uncertain and contingent on closing, taxes, payments to NIH, and other obligations.
• The loan amendment eases certain financial covenants if the PRV monetization reduces the loan balance, which could reduce default risk and provide more operational flexibility; however, it also triggers a mandatory $10M prepayment and depends on the monetization event occurring.
• Investors should note the transactions are subject to closing conditions (including antitrust review) and the company’s statements include forward-looking language about timing and amounts.